Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NUVL

Nuvalent Inc

Nov 30 • 04:00PM ET

65.37

Dollar change +3.17
Percentage change 5.10	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Options Chain • Save to Portfolio • Create Alert

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-2.03	Insider Own	50.03%	Shs Outstand	51.23M	Perf Week	4.59%
Market Cap	4.09B	Forward P/E	-	EPS next Y	-2.86	Insider Trans	-0.70%	Shs Float	31.30M	Perf Month	25.49%
Income	-114.05M	PEG	-	EPS next Q	-0.60	Inst Own	52.46%	Short Float / Ratio	21.03% / 9.28	Perf Quarter	43.45%
Sales	0.00M	P/S	-	EPS this Y	-30.17%	Inst Trans	-1.08%	Short Interest	6.58M	Perf Half Y	53.81%
Book/sh	6.93	P/B	9.44	EPS next Y	-33.16%	ROA	-33.81%	Target Price	75.43	Perf Year	106.61%
Cash/sh	6.60	P/C	9.91	EPS next 5Y	-	ROE	-36.06%	52W Range	23.09 - 65.57	Perf YTD	119.51%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-28.80%	52W High	-0.31%	Beta	1.33
Dividend %	-	Quick Ratio	14.42	Sales past 5Y	0.00%	Gross Margin	-	52W Low	183.05%	ATR	2.62
Employees	62	Current Ratio	14.42	Sales Q/Q	-	Oper. Margin	0.00%	RSI (14)	70.36	Volatility	4.05% 3.58%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	-44.68%	Profit Margin	-	Rel Volume	0.97	Prev Close	62.20
Shortable	Yes	LT Debt/Eq	0.00	Earnings	Nov 14 BMO	Payout	-	Avg Volume	709.48K	Price	65.37
Recom	1.25	SMA20	11.12%	SMA50	19.58%	SMA200	54.16%	Volume	687,785	Change	5.10%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-27-23	Initiated	Stifel	Buy	$65
Aug-08-23	Initiated	SVB Securities	Market Perform	$42
Jul-24-23	Initiated	Guggenheim	Buy	$56
Jan-18-23	Initiated	Wedbush	Outperform	$39
Jun-24-22	Initiated	BMO Capital Markets	Outperform	$28

Nov-14-23 07:15PM	Nuvalent Inc (NUVL) Reports Q3 2023 Financial Results and Pipeline Progress (GuruFocus.com)
06:30AM	Nuvalent Highlights Corporate and Pipeline Achievements and Reports Third Quarter 2023 Financial Results (PR Newswire)
Nov-04-23 07:02AM	Insider Sell: Darlene Noci Sells 3,000 Shares of Nuvalent Inc (NUVL) (GuruFocus.com)
Nov-01-23 06:30AM	Nuvalent to Participate in the BMO Virtual BioPharma Spotlight Series: Oncology Day (PR Newswire)
Oct-23-23 02:50AM	7 Biotech Stocks to Get In Now Before Investors Catch On (InvestorPlace)
06:27PM	Loading…
Oct-17-23 06:27PM	Why Nuvalent Stock Tanked on Tuesday (Motley Fool) -8.28%
Oct-16-23 09:55PM	Nuvalent Announces Pricing of Public Offering of Common Stock (PR Newswire)
07:30AM	Nuvalent Announces Public Offering of Common Stock (PR Newswire)
Oct-13-23 06:30AM	Nuvalent Reports Preliminary Phase 1 Clinical Data from ALKOVE-1 Trial that Support Best-In-Class Potential of NVL-655 for Patients with ALK-Positive NSCLC (PR Newswire)
Oct-07-23 01:00AM	Insider Sell: Chief Medical Officer Christopher Turner Sells 7,995 Shares of Nuvalent Inc (NUVL) (GuruFocus.com)
Oct-05-23 07:13PM	Why Nuvalent Stock Skyrocketed 35% This Week (Motley Fool) +8.52%
10:29AM	Nuvalent (NUVL) Soars 36% on Upbeat Initial NSCLC Study Data (Zacks)
01:01AM	Insider Sell: Darlene Noci Sells 3,000 Shares of Nuvalent Inc (NUVL) (GuruFocus.com)
Oct-04-23 04:13PM	Why Nuvalent Stock Was Soaring Wednesday (Motley Fool) +35.57%
12:21PM	Preliminary Phase 1 Dose-Escalation Data from ALKOVE-1 Trial of NVL-655 Demonstrated Activity in Heavily Pre-Treated Patients with ALK-Positive NSCLC and an ALK-Selective, TRK-Sparing Safety Profile (PR Newswire)
06:30AM	Loading…
Sep-18-23 06:30AM	Nuvalent to Present Preliminary Data from ALKOVE-1 Phase 1/2 Clinical Trial of NVL-655 at 35th AACR-NCI-EORTC Symposium (PR Newswire) -6.08%
Sep-05-23 06:30AM	Nuvalent Initiates the Phase 2 Portion of ARROS-1 Clinical Trial for Patients with ROS1-Positive NSCLC and other Solid Tumors (PR Newswire)
Aug-31-23 06:30AM	Nuvalent to Participate in Upcoming September Investor Conferences (PR Newswire)
Aug-17-23 06:40AM	7 A-Rated Biotech Stocks for Your August Buy List (InvestorPlace)
Aug-10-23 06:30AM	Nuvalent Highlights Pipeline Progress and Reports Second Quarter 2023 Financial Results (PR Newswire)
Aug-08-23 10:02AM	DraftKings upgraded, Home Depot downgraded: Wall Street's top analyst calls (The Fly)
Aug-01-23 06:30AM	Nuvalent to Participate in Upcoming August Investor Conferences (PR Newswire)
Jul-21-23 08:50AM	Recent Price Trend in Nuvalent, Inc. (NUVL) is Your Friend, Here's Why (Zacks)
Jun-07-23 08:50AM	Nuvalent, Inc. (NUVL) Is a Great Choice for 'Trend' Investors, Here's Why (Zacks)
May-24-23 06:30AM	Nuvalent to Participate in the TD Cowen 4th Annual Oncology Innovation Summit (PR Newswire)
May-11-23 06:30AM	Nuvalent Announces Anticipated Timing of Preliminary Phase 1 Dose-Escalation Data for NVL-655 and Reports First Quarter 2023 Financial Results (PR Newswire)
Apr-19-23 06:30AM	Nuvalent to Participate in the Stifel 2023 Virtual Targeted Oncology Days (PR Newswire) +5.13%
Apr-18-23 09:00AM	Nuvalent Presents New Preclinical Data Supporting Intracranial Activity of NVL-655 at AACR Annual Meeting 2023 (PR Newswire)
Apr-02-23 10:56AM	Nuvalent (NASDAQ:NUVL) Is In A Strong Position To Grow Its Business (Simply Wall St.)
Mar-23-23 06:30AM	Nuvalent to Present ALKOVE-1 Trial in Progress Poster for NVL-655 at the European Lung Cancer Congress (ELCC 2023) (PR Newswire)
06:30AM	Loading…
Mar-16-23 06:30AM	Nuvalent Highlights Pipeline and Business Progress and Reports Fourth Quarter and Full Year 2022 Financial Results (PR Newswire) +5.45%
Mar-14-23 05:59PM	Nuvalent to Present New Preclinical Data on ALK-Selective Inhibitor NVL-655 at AACR Annual Meeting 2023 (PR Newswire) +6.05%
Mar-01-23 06:30AM	Nuvalent to Participate in the 43rd Annual Cowen Healthcare Conference (PR Newswire)
Jan-04-23 06:30AM	Nuvalent to Present at the 41st Annual J.P. Morgan Healthcare Conference (PR Newswire)
Jan-02-23 09:40AM	Are Medical Stocks Lagging DICE Therapeutics (DICE) This Year? (Zacks)
Dec-13-22 10:15AM	Nuvalent Announces Publication in Cancer Discovery Detailing Design and Characterization of ROS1-selective inhibitor NVL-520 (PR Newswire)
Dec-12-22 03:44PM	12 Best Small-Cap Healthcare Stocks To Buy Now (Insider Monkey)
Dec-02-22 08:50AM	Here's Why Momentum in Nuvalent, Inc. (NUVL) Should Keep going (Zacks)
Nov-17-22 12:00PM	What Makes Nuvalent, Inc. (NUVL) a Strong Momentum Stock: Buy Now? (Zacks)
Nov-10-22 06:30AM	Nuvalent Reviews Corporate and Pipeline Achievements and Reports Third Quarter 2022 Financial Results (PR Newswire)
Nov-03-22 08:13PM	Nuvalent Announces Closing of Upsized Public Offering of Common Stock (PR Newswire) -6.04%
Oct-31-22 09:14PM	Nuvalent Announces Pricing of Public Offering of Common Stock (PR Newswire)
07:15AM	Nuvalent Announces Public Offering of Common Stock (PR Newswire)
Oct-28-22 04:18PM	Nuvalent stock jumps on positive data from cancer drug trial (American City Business Journals) +60.64%
04:06PM	Recent IPO Stock Nuvalent Is Flirting With A Record High On A Tricky Cancer Win (Investor's Business Daily)
11:10AM	Why Nuvalent Shares Are Surging 45% Today? (Benzinga)
12:01AM	Nuvalent Reports Preliminary Phase 1 Clinical Data from ARROS-1 Trial that Support Best-In-Class Potential of NVL-520 for Patients withROS1-Positive NSCLC (PR Newswire)
Oct-26-22 06:30AM	Nuvalent Announces New Preclinical Data for Selective Kinase Inhibitors NVL-330 and NVL-655 (PR Newswire)
Oct-23-22 09:26AM	We Think Nuvalent (NASDAQ:NUVL) Can Easily Afford To Drive Business Growth (Simply Wall St.)
Oct-17-22 06:30AM	Nuvalent to Host Conference Call to Discuss Preliminary Phase 1 Data from ARROS-1 Clinical Trial of NVL-520 and Additional Preclinical Updates in Conjunction with 34th EORTC-NCI-AACR Symposium (PR Newswire) +6.99%
Oct-06-22 06:30AM	Nuvalent Appoints Michael L. Meyers, MD, PhD, to Board of Directors (PR Newswire)
Sep-20-22 10:16AM	Nuvalent Has Made a Base Pattern on the Charts (TheStreet.com)
Sep-07-22 06:30AM	Nuvalent to Present Preliminary Phase 1 Data from ARROS-1 Clinical Trial of NVL-520 at 34th EORTC-NCI-AACR Symposium and Announces Pipeline Updates (PR Newswire) +17.55%
Sep-01-22 06:30AM	Nuvalent to Participate in the Wells Fargo 2022 Healthcare Conference (PR Newswire)
Aug-10-22 06:30AM	Nuvalent Highlights Execution Across Pipeline of Novel Kinase Inhibitors and Reports Second Quarter 2022 Financial Results (PR Newswire) +12.35%
Aug-05-22 06:30AM	Nuvalent Presents New Preclinical Data Supporting Potential Best-in-Class Profile for ALK-Selective Inhibitor NVL-655 at IASLC 2022 World Conference on Lung Cancer Annual Meeting (PR Newswire)
Aug-03-22 06:30AM	Nuvalent to Present at the Canaccord Genuity 42nd Annual Growth Conference (PR Newswire)
Jul-20-22 06:30AM	Nuvalent Announces Leadership Promotions (PR Newswire) -7.92%
Jul-13-22 06:30AM	Nuvalent to Present New NVL-655 Preclinical Data and ARROS-1 Trial in Progress Poster for NVL-520 at IASLC 2022 World Conference on Lung Cancer Annual Meeting (PR Newswire) +5.39%
Jul-01-22 10:52AM	Nuvalent Has Begun the Bottoming Process (TheStreet.com)
Jun-21-22 06:30AM	Nuvalent Announces Clinical Progress on Parallel Lead Programs NVL-520 and NVL-655 for NSCLC and Solid Tumor Cancers (PR Newswire) +10.18%
Jun-02-22 06:38AM	Nuvalent to Present at the 2022 Jefferies Healthcare Conference (PR Newswire)
May-16-22 09:10AM	Here's Why We're Not At All Concerned With Nuvalent's (NASDAQ:NUVL) Cash Burn Situation (Simply Wall St.) -7.50%
May-12-22 06:30AM	Nuvalent Highlights Pipeline and Business Progress and Reports First Quarter 2022 Financial Results (PR Newswire)
Apr-11-22 07:21AM	Nuvalent Highlights New Data Exhibiting Expanded Preclinical Activity Of NVL-520 In ROS1-Driven Cancers (Benzinga) -6.62%
Apr-08-22 01:15PM	Nuvalent Presents New Data Demonstrating Expanded Preclinical Activity with ROS1-Selective Inhibitor NVL-520 and ALK-Selective Inhibitor NVL-655 at AACR Annual Meeting 2022 (PR Newswire)
Apr-07-22 06:30AM	Nuvalent to Participate in the 2022 Canaccord Genuity Horizons in Oncology Virtual Conference (PR Newswire)
Mar-31-22 06:30AM	Nuvalent Appoints Anna Protopapas as Chair of Board of Directors (PR Newswire)
Mar-29-22 06:30AM	Nuvalent Reports Pipeline and Business Progress and Fourth Quarter and Full Year 2021 Financial Results (PR Newswire) +7.49%
Mar-08-22 05:38PM	Nuvalent to Present New Preclinical Data on ROS1-Selective Inhibitor NVL-520 and ALK-Selective Inhibitor NVL-655 at AACR Annual Meeting 2022 (PR Newswire)
Mar-02-22 06:30AM	Nuvalent to Participate in the Cowen 42nd Annual Healthcare Conference (PR Newswire)
Feb-03-22 06:30AM	Nuvalent Appoints Emily Drabant Conley, PhD, to Board of Directors (PR Newswire)
Jan-07-22 06:30AM	Nuvalent Announces First Patient Dosed in ARROS-1 Phase 1/2 Clinical Trial of NVL-520, its Novel ROS1-selective Inhibitor (PR Newswire)
Jan-04-22 06:30AM	Nuvalent to Present at the 40th Annual J.P. Morgan Healthcare Conference (PR Newswire)
Nov-10-21 06:30AM	Nuvalent Reports Pipeline Progress and Third Quarter 2021 Financial Results (PR Newswire)
Oct-29-21 09:55AM	Here's What Nuvalent, Inc.'s (NASDAQ:NUVL) Shareholder Ownership Structure Looks Like (Simply Wall St.)
Oct-07-21 09:21AM	New Preclinical Data Supports Nuvalent Lead Programs in ROS1-Positive, ALK-Positive NSCLC (PR Newswire) -6.53%
Sep-08-21 06:30AM	Nuvalent Announces Business and Program Highlights and Reports Second Quarter 2021 Financial Results (PR Newswire)
Aug-06-21 06:26PM	Translate Bio, Nuvalent See Activist Action (Barrons.com) -11.19%
Aug-02-21 05:39PM	Nuvalent Announces Closing of Upsized Initial Public Offering (PR Newswire) +20.05%
Jul-28-21 11:22PM	Nuvalent Announces Pricing of Initial Public Offering (PR Newswire)

Nuvalent, Inc. is a clinical stage biopharmaceutical company, which focuses on creating precisely targeted therapies for patients with cancer. Its pipeline includes ROS1 NSCLC, ALK NSCLC and HER2 NSCLC. The company was founded by Matthew Shair in January 2017 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Shair Matthew	Director	Nov 28	Sale	61.89	9,150	566,303	1,843,848	Nov 30 04:47 PM
Noci Darlene	Chief Development Officer	Nov 01	Option Exercise	1.08	3,000	3,240	3,000	Nov 03 04:43 PM
Noci Darlene	Chief Development Officer	Nov 01	Sale	52.66	3,000	157,975	0	Nov 03 04:43 PM
Shair Matthew	Director	Oct 24	Sale	50.70	91,700	4,648,872	1,852,998	Oct 26 04:47 PM
Noci Darlene	Chief Development Officer	Oct 04	Option Exercise	5.56	20,000	111,150	20,000	Oct 06 04:56 PM
Turner Christopher Durant	Chief Medical Officer	Oct 04	Option Exercise	6.89	7,995	55,086	22,508	Oct 06 04:58 PM
Noci Darlene	Chief Development Officer	Oct 04	Sale	55.99	20,000	1,119,702	0	Oct 06 04:56 PM
Turner Christopher Durant	Chief Medical Officer	Oct 04	Sale	54.04	7,995	432,031	14,513	Oct 06 04:58 PM
Noci Darlene	Chief Development Officer	Oct 02	Option Exercise	1.08	3,000	3,240	3,000	Oct 04 04:24 PM
Noci Darlene	Chief Development Officer	Oct 02	Sale	45.88	3,000	137,649	0	Oct 04 04:24 PM
Miller Deborah Ann	Chief Legal Officer	Sep 15	Option Exercise	6.89	2,000	13,780	2,000	Sep 19 04:45 PM
Miller Deborah Ann	Chief Legal Officer	Sep 15	Sale	47.64	2,000	95,283	0	Sep 19 04:45 PM
Noci Darlene	Chief Development Officer	Sep 01	Option Exercise	1.08	3,000	3,240	3,000	Sep 06 04:36 PM
Noci Darlene	Chief Development Officer	Sep 01	Sale	46.56	3,000	139,692	0	Sep 06 04:36 PM
Miller Deborah Ann	Chief Legal Officer	Aug 15	Option Exercise	6.89	2,000	13,780	2,000	Aug 17 04:29 PM
Miller Deborah Ann	Chief Legal Officer	Aug 15	Sale	42.65	2,000	85,310	0	Aug 17 04:29 PM
Noci Darlene	Chief Development Officer	Aug 01	Option Exercise	1.08	3,000	3,240	3,000	Aug 01 05:26 PM
Noci Darlene	Chief Development Officer	Aug 01	Sale	49.95	3,000	149,844	0	Aug 01 05:26 PM
Balcom Alexandra	Chief Financial Officer	Jul 31	Option Exercise	1.08	25,000	27,000	25,000	Aug 01 04:16 PM
Balcom Alexandra	Chief Financial Officer	Jul 31	Sale	48.99	25,000	1,224,796	0	Aug 01 04:16 PM
Miller Deborah Ann	Chief Legal Officer	Jul 28	Option Exercise	6.89	6,500	44,785	6,500	Aug 01 04:13 PM
Turner Christopher Durant	Chief Medical Officer	Jul 28	Option Exercise	6.89	2,665	18,362	17,178	Jul 28 04:51 PM
Miller Deborah Ann	Chief Legal Officer	Jul 28	Sale	48.52	6,500	315,380	0	Aug 01 04:13 PM
Turner Christopher Durant	Chief Medical Officer	Jul 28	Sale	48.93	2,665	130,398	14,513	Jul 28 04:51 PM
Turner Christopher Durant	Chief Medical Officer	Jul 26	Option Exercise	6.89	2,365	16,295	16,878	Jul 28 04:51 PM
Turner Christopher Durant	Chief Medical Officer	Jul 26	Sale	46.85	2,365	110,800	14,513	Jul 28 04:51 PM
Turner Christopher Durant	Chief Medical Officer	Jul 24	Option Exercise	6.89	200	1,378	14,713	Jul 24 04:54 PM
Turner Christopher Durant	Chief Medical Officer	Jul 24	Sale	46.82	200	9,364	14,513	Jul 24 04:54 PM
Noci Darlene	Chief Development Officer	Jul 20	Option Exercise	1.08	10,941	11,816	10,941	Jul 21 04:47 PM
Turner Christopher Durant	Chief Medical Officer	Jul 20	Option Exercise	6.89	100	689	14,613	Jul 24 04:54 PM
Noci Darlene	Chief Development Officer	Jul 20	Sale	45.17	10,941	494,205	0	Jul 21 04:47 PM
Turner Christopher Durant	Chief Medical Officer	Jul 20	Sale	46.80	100	4,680	14,513	Jul 24 04:54 PM
Noci Darlene	Chief Development Officer	Jul 19	Option Exercise	1.08	4,559	4,924	4,559	Jul 21 04:47 PM
Noci Darlene	Chief Development Officer	Jul 19	Sale	45.04	4,559	205,337	0	Jul 21 04:47 PM
Miller Deborah Ann	Chief Legal Officer	Jul 17	Option Exercise	6.89	2,000	13,780	2,000	Jul 19 04:43 PM
Miller Deborah Ann	Chief Legal Officer	Jul 17	Sale	43.06	2,000	86,123	0	Jul 19 04:43 PM
Noci Darlene	Chief Development Officer	Jul 03	Option Exercise	1.08	3,000	3,240	3,000	Jul 06 04:51 PM
Noci Darlene	Chief Development Officer	Jul 03	Sale	41.48	3,000	124,427	0	Jul 06 04:51 PM
Noci Darlene	Chief Development Officer	Jun 16	Option Exercise	1.08	2,900	3,132	2,900	Jun 20 04:45 PM
Noci Darlene	Chief Development Officer	Jun 16	Sale	45.19	2,900	131,051	0	Jun 20 04:45 PM
Miller Deborah Ann	Chief Legal Officer	Jun 15	Option Exercise	6.89	2,000	13,780	2,000	Jun 20 04:42 PM
Noci Darlene	Chief Development Officer	Jun 15	Option Exercise	1.08	1,000	1,080	1,000	Jun 20 04:45 PM
Miller Deborah Ann	Chief Legal Officer	Jun 15	Sale	44.28	2,000	88,565	0	Jun 20 04:42 PM
Noci Darlene	Chief Development Officer	Jun 15	Sale	45.07	1,000	45,070	0	Jun 20 04:45 PM
Turner Christopher Durant	Chief Medical Officer	Jun 05	Option Exercise	6.89	10,235	70,519	24,748	Jun 07 04:50 PM
Noci Darlene	Chief Development Officer	Jun 05	Option Exercise	1.08	600	648	600	Jun 07 04:46 PM
Turner Christopher Durant	Chief Medical Officer	Jun 05	Sale	44.86	10,235	459,142	14,513	Jun 07 04:50 PM
Noci Darlene	Chief Development Officer	Jun 05	Sale	45.00	600	27,000	0	Jun 07 04:46 PM
Noci Darlene	Chief Development Officer	Jun 01	Option Exercise	1.08	3,000	3,240	3,000	Jun 02 04:45 PM
Noci Darlene	Chief Development Officer	Jun 01	Sale	42.64	3,000	127,921	0	Jun 02 04:45 PM
Miller Deborah Ann	Chief Legal Officer	May 15	Option Exercise	6.89	2,000	13,780	2,000	May 17 04:44 PM
Miller Deborah Ann	Chief Legal Officer	May 15	Sale	40.74	2,000	81,489	0	May 17 04:44 PM
Miller Deborah Ann	Chief Legal Officer	May 09	Option Exercise	6.89	1,332	9,177	1,332	May 09 05:11 PM
Miller Deborah Ann	Chief Legal Officer	May 09	Sale	39.63	1,332	52,787	0	May 09 05:11 PM
Miller Deborah Ann	Chief Legal Officer	May 05	Option Exercise	6.89	2,800	19,292	2,800	May 09 05:11 PM
Miller Deborah Ann	Chief Legal Officer	May 05	Sale	39.64	2,800	110,992	0	May 09 05:11 PM
Miller Deborah Ann	Chief Legal Officer	May 01	Option Exercise	6.89	900	6,201	900	May 03 04:38 PM
Noci Darlene	Chief Development Officer	May 01	Option Exercise	1.08	3,000	3,240	3,000	May 03 04:41 PM
Noci Darlene	Chief Development Officer	May 01	Sale	38.60	3,000	115,787	0	May 03 04:41 PM
Miller Deborah Ann	Chief Legal Officer	May 01	Sale	39.61	900	35,649	0	May 03 04:38 PM
Miller Deborah Ann	Chief Legal Officer	Apr 17	Option Exercise	6.89	2,000	13,780	2,000	Apr 19 04:46 PM
Miller Deborah Ann	Chief Legal Officer	Apr 17	Sale	30.10	2,000	60,198	0	Apr 19 04:46 PM
Noci Darlene	Chief Development Officer	Apr 03	Option Exercise	1.08	3,000	3,240	3,000	Apr 05 04:40 PM
Noci Darlene	Chief Development Officer	Apr 03	Sale	26.59	3,000	79,765	0	Apr 05 04:40 PM
Miller Deborah Ann	Chief Legal Officer	Mar 15	Option Exercise	6.89	2,000	13,780	2,000	Mar 17 04:38 PM
Miller Deborah Ann	Chief Legal Officer	Mar 15	Sale	28.25	2,000	56,509	0	Mar 17 04:38 PM
Noci Darlene	Chief Development Officer	Mar 01	Option Exercise	1.08	3,000	3,240	3,000	Mar 03 04:35 PM
Noci Darlene	Chief Development Officer	Mar 01	Sale	29.88	3,000	89,646	0	Mar 03 04:35 PM
Miller Deborah Ann	Chief Legal Officer	Feb 15	Option Exercise	6.89	2,000	13,780	2,000	Feb 17 04:19 PM
Miller Deborah Ann	Chief Legal Officer	Feb 15	Sale	29.56	2,000	59,127	0	Feb 17 04:19 PM
Noci Darlene	Chief Development Officer	Feb 02	Option Exercise	1.08	3,000	3,240	3,000	Feb 03 04:45 PM
Noci Darlene	Chief Development Officer	Feb 02	Sale	29.56	3,000	88,667	0	Feb 03 04:45 PM
Miller Deborah Ann	Chief Legal Officer	Jan 17	Option Exercise	6.89	2,000	13,780	2,000	Jan 19 04:48 PM
Miller Deborah Ann	Chief Legal Officer	Jan 17	Sale	32.62	2,000	65,242	0	Jan 19 04:48 PM
Shair Matthew	Director	Jan 04	Sale	28.04	18,300	513,106	1,944,698	Jan 06 04:42 PM
Miller Deborah Ann	Chief Legal Officer	Dec 15	Option Exercise	6.89	2,000	13,780	2,000	Dec 16 04:48 PM
Noci Darlene	Chief Development Officer	Dec 15	Option Exercise	1.08	4,200	4,536	4,200	Dec 16 04:46 PM
Noci Darlene	Chief Development Officer	Dec 15	Sale	29.91	4,200	125,635	0	Dec 16 04:46 PM
Miller Deborah Ann	Chief Legal Officer	Dec 15	Sale	29.98	2,000	59,955	0	Dec 16 04:48 PM
Shair Matthew	Director	Dec 07	Sale	31.17	18,300	570,458	1,962,998	Dec 09 04:45 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

NUVL

Nuvalent Inc

Upgrade your FINVIZ experience